1. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma

   • Xavier García del Muro
   • Enrique Gallardo
   • Daniel Castellano

   Review Article 16 February 2014 Pages: 1095 - 1107

2. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers

   • Robert C. Shumaker
   • Meijian Zhou
   • Borje Darpo

   Original Article 23 March 2014 Pages: 1109 - 1117

   

3. An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma

   • Mona Darwish
   • John M. Burke
   • Mary Bond

   Original Article Open access 28 March 2014 Pages: 1119 - 1127

   

4. Addition of aprepitant improves protection against cisplatin-induced emesis when a conventional anti-emetic regimen fails

   • Weiheng Hu
   • Jian Fang
   • Jindi Han

   Original Article 21 April 2014 Pages: 1129 - 1136

   

5. Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993)

   • Joel M. Reid
   • Sarah A. Buhrow
   • Matthew M. Ames

   Original Article 24 April 2014 Pages: 1137 - 1146

   

6. Treatment results and prognostic factors for advanced squamous cell carcinoma of the hypopharynx treated with concurrent chemoradiotherapy

   • Takahide Taguchi
   • Goshi Nishimura
   • Nobuhiko Oridate

   Original Article 23 March 2014 Pages: 1147 - 1154

7. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis

   • Yan Wang
   • Yi-yi Yu
   • Tian-shu Liu

   Original Article Open access 21 April 2014 Pages: 1155 - 1161

   

8. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy

   • Faruk Tas
   • Senem Karabulut
   • Derya Duranyildiz

   Original Article 20 March 2014 Pages: 1163 - 1171

   

9. Phase I and pharmacokinetic study of polymeric micelle-formulated paclitaxel in adult Chinese patients with advanced solid tumors

   • Fangfang Lv
   • Junning Cao
   • Jin Li

   Original Article 23 March 2014 Pages: 1173 - 1179

   

10. Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy

    • Jessica Mwinyi
    • Kerstin Vokinger
    • Andreas Trojan

    Original Article 29 March 2014 Pages: 1181 - 1188

    

11. Pharmacokinetics of pazopanib administered in combination with bevacizumab

    • Diane-Charlotte Imbs
    • Sylvie Négrier
    • Etienne Chatelut

    Original Article 06 April 2014 Pages: 1189 - 1196

    

12. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients

    • Katherine M. Slusarz
    • Vanessa L. Merker
    • Scott R. Plotkin

    Original Article 08 April 2014 Pages: 1197 - 1204

    

13. Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors

    • Ramon Salazar
    • Serafin Morales
    • Antonio Llombart

    Original Article 18 April 2014 Pages: 1205 - 1215

    

14. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease

    • Moon Ki Choi
    • Jung Yong Hong
    • Jin Seok Ahn

    Original Article 03 April 2014 Pages: 1217 - 1225

    

15. An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck

    • Vassiliki Saloura
    • Ezra E. W. Cohen
    • Thomas C. Gauler

    Original Article 09 April 2014 Pages: 1227 - 1239

    

16. An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors

    • Pierre Maison-Blanche
    • Shaker Dakhil
    • James L. Wade

    Original Article 10 April 2014 Pages: 1241 - 1252

    

17. Safety analysis of two different regimens of uracil–tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial

    • Takashi Tsuchiya
    • Sotaro Sadahiro
    • Shigetoyo Saji

    Original Article Open access 18 April 2014 Pages: 1253 - 1261

    

18. Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells

    • Sudipa S. Roy
    • Nameer B. Kirma
    • Joseph K. Agyin

    Original Article 12 April 2014 Pages: 1263 - 1271

    

19. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells

    • Kaamar Azijli
    • Ingrid A. M. van Roosmalen
    • Frank A. E. Kruyt

    Original Article 18 April 2014 Pages: 1273 - 1283

    

20. Pharmacokinetics and exposure–effect relationships of capecitabine in elderly patients with breast or colorectal cancer

    • Z. Daher Abdi
    • S. Lavau-Denes
    • A. Rousseau

    Original Article 07 May 2014 Pages: 1285 - 1293

    

21. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)

    • Masanori Toyoda
    • Tetsuo Ajiki
    • Tatsuya Ioka

    Clinical Trial Report Open access 11 March 2014 Pages: 1295 - 1301

22. Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction

    • L. L. Krens
    • J. M. Baas
    • H. Gelderblom

    Short Communication 06 April 2014 Pages: 1303 - 1306

    

23. Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase

    • C. A. Fernandez
    • E. Stewart
    • P. K. Campbell

    Short Communication 27 April 2014 Pages: 1307 - 1313